Hypersensitivity reactions to anticancer agents: Data mining of the public version of the FDA adverse event reporting system, AERS

Table 3 Signal detection for anticancer agent-associated severe hypersensitivity reactions

	N	PRR (χ2)	ROR (95% two-sided CI)	IC (95% two-sided CI)	EBGM (95% one-sided CI)
paclitaxel	79	2.273 * (55.041)	2.278 * (1.826, 2.730)	1.151 * (0.833, 1.469)	2.174 (1.803)
docetaxel	18	0.588 (4.805)	0.587 (0.370, 0.805)	-0.773 (-1.431, -0.115)	0.591 (0.401)
doxorubicin	41	1.036 (0.021)	1.036 (0.762, 1.309)	0.032 (-0.408, 0.471)	1.014 (0.782)
5-fluorouracil	44	1.320 (3.102)	1.321 (0.982, 1.659)	0.374 (-0.051, 0.799)	1.276 (0.994)
cyclophosphamide	51	0.871 (0.851)	0.871 (0.661, 1.080)	-0.209 (-0.604, 0.185)	0.862 (0.683)

The total number of co-occurrences with severe hypersensitivity reactions was 18,255.
N: the number of co-occurrences of each anticancer agent out of 18,255 pairs, PRR: the proportional reporting ratio, ROR: the reporting odds ratio, IC: the information component, EBGM: the empirical Bayes geometric mean.
*: signal detected, see "Methods" for the detection criteria.

ISSN: 1756-9966